"id","name","uuid:ID","label","instanceType","description","rationale"
"StudyDesign_1","Study Design 1","6e045515-39d1-488d-bc89-40242564e689","","StudyDesign","The main design for the study","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
